During the 25th Congress of the European Hematology Association (EHA), the AML Hub spoke to Courtney DiNardo, MD Anderson Cancer Center, Houston, US, about the treatment of elderly patients with AML in 2020.

Courtney DiNardo discusses highlights including the Viale-A trial (evaluating azacitidine + venetoclax for newly diagnosed AML), identifying the benefit of oral azacitidine maintenance, the use of IDH1/2 and FLT-3 inhibitors in the relapsed/refractory setting, the p53 modulating compound APR246, and the CD47 monoclonal antibody magrolimab.

свернуть